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Cytotoxic T lymphocytes (CTL) play a significant role in the clearance of respiratory syncytial virus (RSV) infection in humans and
mice. Identification of class I MHC-restricted CTL epitopes is critical in elucidating mechanisms of CTL responses against viral
infections. However, only four H-2d-restricted epitopes have been reported in mice. Because of the diversity of transgenic and knockout
mice available to study immune responses, new epitopes in additional strains of mice must be identified. We therefore attempted to
discover novel CTL epitopes in C57Bl/6 mice. Our efforts revealed a new H-2Db-restricted CTL epitope from the RSV M protein,
corresponding to aa 187–195 (NAITNAKII). Also, M187–195-specific CTLs were activated with kinetics similar to the
immunodominant BALB/c epitope, M2 82–90. This is the first RSV-specific CTL epitope described in a strain of mice other than
BALB/c. Furthermore, identification of this H-2b-restricted CTL epitope provides access to genetically modified H-2b mice for more
detailed studies of CTL mechanisms in RSV infection.
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Human respiratory syncytial virus (RSV) has long been
the scourge of the young. RSV is the most common cause of
serious viral lower respiratory tract illness observed in
infants and young children (Collins et al., 2001; Glezen and
Denny, 1973). Although RSV infections usually cause a
mild upper respiratory tract infection, severe lower respira-
tory tract disease results in as many as 130,000 pediatric
hospitalizations annually in the United States (Shay et al.,
1999). RSV infection has been associated with 43%–74%
of bronchiolitis cases and 19% to 54% of pneumonia cases0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.04.032
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E-mail address: bgraham@nih.gov (B.S. Graham).(Brandt et al., 1973; Caul et al., 1976; Dagan et al., 1993;
Kim et al., 1973; Saijo et al., 1993; Sims et al., 1976; Yun et
al., 1995). During the 1985–1994 winter seasons in
Rochester, New York, RSV infection was associated with
50%–80% of bronchiolitis hospitalizations and 30%–60%
of pneumonia hospitalizations (Hall, 1998). In addition, a
correlation between RSV and high mortality in the
institutionalized elderly and the immunocompromised,
particularly bone marrow transplant recipients, has been
documented (Falsey and Walsh, 2000; Hertz et al., 1989).
For these reasons, the development of an effective RSV
vaccine remains a high priority (Cohen, 1994). However,
vaccine development has been hampered by the legacy of
failed vaccine trials in the 1960s. A formalin-inactivated,
alum-precipitated RSV preparation (FI-RSV) caused more
severe illness, increased rates of hospitalization, and some05) 335 – 343
Table 1
Example of the overlapping peptide strategy used to test peptides by
ELISpot
Peptide Sequence
F1 – 14 MELLILKANAITTI
F4 – 17 LILKANAITTILTA
F7– 20 KANAITTILTAVTF
F10 – 23 AITTILTAVTFCFA
Overlapping 14 or 15 aa peptides from the F, G, and M proteins of RSV
were tested by INF-g ELISpot analysis. As an example of the strategy
employed, the sequences of the first 4 in the series of F peptides are shown.
The same approach was used for the G and M proteins.
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et al., 1969; Kim et al., 1969).
Cytotoxic T lymphocytes (CTL) are essential constitu-
ents of the immune response to most viral infections
(Doherty and Christensen, 2000; Harty et al., 2000; Wong
and Pamer, 2003). Studies in the murine model of RSV have
determined that CTLs are the most important immune cells
for clearance of virus-infected epithelial cells (Graham,
1996; Graham et al., 1991). However, T cells also contribute
to the RSV-associated immunopathology that is observed
during the infection (Graham, 1996; Graham et al., 2002). In
mice, depletion of CD4+ and CD8+ T cells led to an
extended period of virus replication and no visible illness
(Graham et al., 1991). When CD8+ T cells alone were
depleted, virus clearance was delayed and illness was
diminished (Graham et al., 1991). In contrast, illness was
exacerbated when excess RSV-specific CTLs were trans-
ferred to recipient mice (Cannon et al., 1988). Additional
studies have shown strong CTL responses in mice that were
immunized with vaccinia viruses co-expressing several
different RSV proteins (Bangham et al., 1986; Nicholas et
al., 1991; Openshaw et al., 1990). More recent studies in
mice have shown that perforin/granzyme killing and gamma
interferon (IFN-g) are protective, but exaggerated produc-
tion of tumor necrosis factor alpha (TNF-a) during the
effector phase of the immune response exacerbates immu-
nopathology (Aung et al., 2001; Rutigliano and Graham,
2004). These data are consistent with the idea that an
overzealous CTL response causes immunopathology in
primary RSV infection of mice.
Most strains of mice are susceptible to RSV infection,
although BALB/c mice are among the most permissive
(Prince et al., 1979), and the overwhelming majority of
studies on the pathogenesis of vaccine-enhanced illness in
mice have been performed in the BALB/c strain. It is
therefore not surprising that all four previously described
RSV-specific CTL epitopes were identified in BALB/c
mice (Chang et al., 2001; Jiang et al., 2002; Johnstone
et al., 2004; Kulkarni et al., 1993). Many transgenic and
knockout mice are available only on other genetic back-
grounds. Therefore, it is important to identify RSV-specific
CTL epitopes in other strains of mice. The identification of
non-H-2d-restricted CTL epitopes would make other strains
available for studying the immunology of CD8+ CTLs
prior to backcrossing onto an H-2d background. To this
end, we attempted to identify new RSV-specific CTL
epitopes in H-2b mice, one of the most popular genetic
backgrounds used in the development of genetically altered
mice. In this report, we define a novel H-2Db-restricted
RSV-specific CTL epitope. This CTL epitope is derived
from the matrix protein and spans amino acids 187–195.
With this new CTL epitope, more comprehensive studies
concerning the regulation of the CTL response and
mechanisms of viral clearance and immunopathology in
the setting of RSV can now be carried out in mice on the
H-2Db background.Results
Identification of potential H-2b-restricted CTL epitopes by
ELISpot analysis
We initially sought to identify potential CTL epitopes in
RSV immune C57Bl/6 mice by enumeration of peptide-
specific INF-g spot-forming cells by ELISpot analysis. To
accomplish this, we utilized a panel of 14 or 15 aa peptides,
overlapping by 11 aa (illustrated in Table 1), spanning the F,
G, or M proteins of RSV (Table 2). These peptide sets were
used in ELISpot assays to screen BALB/c and C57Bl/6 mice.
Splenocytes were isolated from RSV-immunemice on day 14
post-challenge and were tested against individual peptides in
duplicate. The number of SFC/106 input cells was deter-
mined. Splenocytes from RSV-challenged BALB/c mice
pulsed with the immunodominant M2 82–90 peptide were
used as a peptide positive control. Fourteen of the 351 pep-
tides tested elicited an IFN-gELISpot response of >100 SFC/
106 input cells (Table 2). Anything up to 100 SFC/106 input
cells was considered background. Interestingly, the predom-
inant response of BALB/c mice was directed against the F
protein, while the C57Bl/6 response was directed against the
M protein. The largest responses in the F protein were
observed against peptides containing the previously defined
H2-Dd restricted epitope F85–93 (KYKNAVTEL) (Chang et
al., 2001) and around the previously described 15-mer region
F92–106 (ELQLLMQSTPPTNNR) (Jiang et al., 2002).
Confirmation of ELISpot results by flow cytometry
To further evaluate the candidate epitope responses
identified by ELISpot, we next performed intracellular
cytokine staining (ICS) for IFN-g production by CD8+ T
cells. We chose to focus our evaluation on consecutive
peptides that both satisfied our criteria for a positive
ELISpot response, which was >100 SFC/106 input cells.
We reasoned that a legitimate epitope would evoke a
response in both adjacent peptides since the sequence
would be found in the overlap region. The only peptides
that satisfied this requirement were M181–195 and M185–
199, which induced a positive ELISpot response in C57Bl/6
mice. As negative controls, we chose a random full-length
peptide from the F and G proteins for use in our ICS assays.
Fig. 1. Screening of ELISpot-positive peptides by ICS. Several full-length
peptides were positive for IFN-g production by ELISpot. The adjacent full-
length M181–195 and M185–199 peptides were then screened for IFN-g
production by ICS to confirm that they induced an RSV-specific CD8+ T
cell response. Mice were immunized with RSV and challenged 1 month
later with live virus. On day 14 post-challenge, mice were sacrificed and
splenocytes were analyzed by ICS using the peptides shown. Splenocytes
stimulated with PMA/ionomycin and H-2d BALB/c splenocytes stimulated
with RSV M2 82–90 (H-2Kd) as positive controls. As negative controls, H-
2b C57BL/6 splenocytes were also stimulated with RSV M2 82–90, in
addition to full-length peptides from the F (aa 556–569; PVTLSKD-
QLSGINN) and G (aa 161–175; NDFHFEVFNFVPCSI) proteins of RSV.
N = 5 mice per group. The data are a representative of 3 independent
experiments with similar results.
Table 2
ELISpot-positive peptides in BALB/c and C57Bl/6 mice
Strain Protein AA pos. SFC Sequence Tested
BALB/c F 4–17 115 LILKANAITTILTA No
BALB/c F 67–80 105 NKCNGTDAKVKLIK No
BALB/c F 82–95 260 ELDKYKNAVTELQL Chang
et al.,
2001
BALB/c F 85–98 185 KYKNAVTELQLLMQ Chang
et al.,
2001
BALB/c F 94–10 175 QLLMQSTPATNNRA Jiang
et al.,
2002
BALB/c F 97–110 190 MQSTPATNNRARRE Jiang
et al.,
2002
BALB/c F 388–401 110 NPKYDCKIMTSKTD No
C57Bl/6 G 149–163 134 KQRQNKPPSKPNNDF No
C57Bl/6 M 181–195 149 TTTEFKNAITNAKII Yes
C57Bl/6 M 185–199 106 FKNAITNAKIIPYSG Yes
C57Bl/6 M 201–215 131 LLVITVTDNKGAFKY No
C57Bl/6 M 209–223 106 NKGAFKYIKPQSQFI No
C57Bl/6 M 233–247 119 ESIYYVTTNWKHTAT No
Positive results were identified as wells with an IFN-g ELISpot response of
>100 SFC/106 input cells. Those peptides that yielded a positive response
are presented in the table. The aa position indicates the amino acid numbers
of the indicated sequences. SFC indicates the number of SFC/106 input
cells in the ELISpot assay. Anything up to 100 SFC/106 input cells was
considered background. Tested indicates whether or not we performed ICS
with the peptide, or if another group had previously identified and tested a
peptide within the given region. ELISpots were performed at least twice,
with similar results each time.
Table 3
Short peptides used to determine the optimal epitope length from the
M181–199 and M185–199 peptides
Peptide Sequence
M186–195 KNAITNAKII
M187–195 NAITNAKII
M188–195 AITNAKII
M188–196 AITNAKIIP
M188–197 AITNAKIIPY
Five short peptides from the overlap region in the M181–195 and M185–
199 peptides were synthesized based on epitope prediction computer
algorithms to identify the optimal CTL epitope. ICS was used to test these
8–10 aa peptides for IFN-g production by CD8+/CD3+ T cells using
splenocytes isolated on day 14 post-challenge.
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splenocytes were pulsed with the full-length 14 or 15 aa
peptides. As seen in Fig. 1, both the M181–195 and M185–
199 peptides were positive by ICS. Because these peptides
were in adjacent locations in the matrix protein, we
surmised that a single epitope in C57Bl/6 mice was located
in the overlap region of the two peptides. Both of these
peptides induced significantly higher levels of IFN-g
production than full-length negative control peptides from
other RSV proteins. Both M181–195 and M185–199
induced IFN-g production by approximately 3.5% of
CD8+ T cells. This level of IFN-g production was similar
to that induced by the known M2 82–90 peptide epitope in
BALB/c mice, in which 2.5% of CD8+ T cells produced
IFN-g. A PMA/ionomycin-stimulated positive control in-
duced nearly 25% of CD8+/CD3+ T cells to produce IFN-g
(data not shown), and C57Bl/6 splenocytes stimulated with
the influenza NP peptide and H-2d M2 82–90 epitope
yielded background levels of IFN-g production (<0.05%),
as expected in these H-2b background mice.
Characterization of the optimal 9 aa epitope within the
M181–195 and M185–199 peptides
Because a 15-aa peptide is unstable within the class I
MHC groove due to steric hindrance and length constraints,we endeavored to define the optimal epitope in the M181–
195 and M185–199 peptides. As a starting point, we relied
on the computer algorithm programs described in Materials
and methods. All three algorithms predicted a 9-aa peptide
epitope for H-2b beginning with residue 187 of the M protein.
We then synthesized five new, truncated overlapping peptides
(Table 3) and tested these for IFN-g production by ICS. The
data showed that M186–195 and M187–195 both induced
significant IFN-g production in CD8+ T cells at day 14 post-
challenge (Fig. 2). M186–195 induced approximately 2.5%
of CD8+ T cells to produce IFN-g, and nearly 3.0% of CD8+
T cells produced IFN-g in response to M187–195. The
M187–195 peptide therefore induced the most robust IFN-g
Fig. 3. M187–195 is H-2Db restricted. P815 target cells that express H-2d
were pulsed with M2 82–90 peptide. L-Db (H-2Db) and L-Kb (H-2Kb)
target cells were pulsed with M187–195 peptide. These targets were then
stained with 5 AM CFSE (CFSE high) and incubated with lymphocytes
isolated from the lungs of RSV-infected BALB/c mice (P815) or C57Bl/6
mice (L-Db and L-Kb) on day 8 post-infection. After a 2- to 4-h incubation
at 37-, the cells were examined by flow cytometry to assess specific lysis of
RSV-infected target cells at various effector/target cell ratios. As a negative
control, separate populations of all target cells were pulsed with an
irrelevant influenza NP peptide and stained with 0.5 AM CFSE (CFSE low)
to distinguish them from their RSV peptide-pulsed counterparts. Equivalent
numbers of CFSE high and low targets were coincubated with effectors, and
RSV-specific lysis was determined by calculating 100(percent of CFSE
high cells/percent of CFSE low cells). The data are a single representative
of at least 5 experiments. At least 5 mice were used per experiment.
Fig. 2. Determination of optimal CD8+ CTL epitope from the RSV M
protein in C57Bl/6 mice. Truncated peptides were synthesized based on the
optimal peptide length of the overlap region in the M181–195 and M185–
199 peptides as predicted by epitope prediction computer algorithms. These
peptides were then tested for their ability to induce IFN-g production by
CD8+/CD3+ T cells in RSV-challenged mice at day 14 post-infection.
N = 5 mice per group. The data are a representative of 3 independent
experiments with similar results.
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stimulated positive control yielded over 30% IFN-g positive
cells (data not shown), and splenocytes stimulated with the
influenza NP or H-2dM2 82–90 peptide epitopes yielded less
than 0.05% IFN-g positive cells. From these data, we
determined that M187–195 is the optimal 9 aa epitope
recognized by CD8+ T cells in C57Bl/6 mice. M187–195
gave themost robust IFN-g response, fits the canonical length
for a class I MHC epitope, and was predicted by every
computer algorithm to be the optimal epitope. We therefore
used this peptide in all subsequent experiments.
The M187–195 epitope is H-2Db restricted
With the optimal 9 aa peptide epitope defined, we next
sought to determine its class I MHC restriction. To
accomplish this, we used several cell lines with different
class I MHC expression patterns in a variation of
previously described fluorescent-based lytic assays (Betts
et al., 2003; Liu et al., 2002; Oehen and Brduscha-Riem,
1998; van Stipdonk et al., 2003). P815 cells express H-2d
class I MHC molecules, and L-Kb and L-Db cells express
only H-2Kb or H-2Db, respectively. P815 cells were pulsed
with the M2 82–90 peptide and were incubated with
BALB/c lung lymphocytes as a positive control. The L-Kb
and L-Db cells were pulsed with the M187–195 peptide
and were incubated with C57Bl/6 lung lymphocytes. A
separate population of all three cell lines was pulsed with
the irrelevant influenza NP 147–155 peptide to serve as a
negative control. RSV peptide-pulsed targets were stained
with 5 AM CFSE (CFSE high) and influenza-pulsed targets
were pulsed with 0.5 AM CFSE (CFSE low). RSV-infectedBALB/c and C57Bl/6 mice were sacrificed on d8 post-
infection, and lung lymphocytes were isolated for use in
the cytolytic assay. Effector cells and target cells were
incubated at ratios of 40:1, 20:1, and 10:1 for 2–4 h at
37 -C in v-bottom plates. Equivalent numbers of CFSE
high and low targets were incubated simultaneously with
the effectors. Because the CFSE low targets express an
influenza peptide, there should be no response to them and
no interference with the response to the CFSE high targets
that have been pulsed with RSV peptides. At the
conclusion of the incubation, the cells were analyzed by
flow cytometry to determine specific lysis by the lung
lymphocytes. The data showed that the M187–195 peptide
epitope was H-2Db restricted (Fig. 3), consistent with the
computer algorithm predictions. Significant levels of RSV-
specific lysis were observed at all E/T ratios with P815 and
L-Db targets, but lysis was not detected using L-Kb target
cells. These results confirmed that the RSV M187–195
peptide epitope is H-2Db-restricted.
The pattern of the M187–195-induced CD8+ T cell
response in C57Bl/6 mice is similar to that of M2 82–90
in BALB/c mice
The M2 82–90 peptide induces a robust CD8+ T cell
response in BALB/c mice. We therefore decided to compare
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M187–195 epitope in C57Bl/6 mice to the M2 82–90
epitope in BALB/c mice. Mice were infected with RSV and
sacrificed at days 4, 6, 8, 10, 15, and 30 post-infection. ICS
was used to determine the absolute number of CD8+ T cells
producing IFN-g at each time point. The kinetics of the
response to each epitope was similar, with the number of
CD8+ T cells producing IFN-g increasing through day 6 in
the lungs, then waning from day 8 through the completion
of the experiment (Fig. 4A). The number of CD8+ T cells
producing IFN-g in the lungs was significantly reduced in
C57Bl/6 mice at all time points except day 6, but the
kinetics of the response did mirror that which was observed
in BALB/c mice. This is not surprising, given that C57Bl/6Fig. 4. The CD8+ CTL response to M187–195 exhibits similar kinetics and
potency to the CD8+ CTL response to M2 82–90. C57Bl/6 and BALB/c
mice were infected with RSV and sacrificed at days 4, 6, 8, 10, 15, and 30
post-infection. (A) CD8+/CD3+ T cell function and activity were measured
by ICS for IFN-g using lung lymphocytes through day 15 post-infection.
(B) Memory CD8+/CD3+ T cell function and activity were measured by
ICS for IFN-g using splenic lymphocytes on day 30 post-infection. N = 5
on each day. The data are a representative of 2 independent experiments.
P < 0.05 at all time points except day 6 in panel A.mice are less permissive to RSV infection and generally
show an attenuated response to the infection. We also noted
that there appeared to be a slight increase in the number of
responding CD8+ T cells in BALB/c mice at day 10
compared to day 8. However, this was considered not to be
biologically significant and more likely related to minor
variation in assay conditions from day to day. We
additionally examined the ability of memory CD8+ T cells
to respond to M2 82–90 and M187–195 by ICS for IFN-g
production by CD8+ T cells. Memory CD8+ T cells isolated
from the spleen on day 30 showed a similar pattern to what
we observed in the lungs, with significantly more CD8+ T
cells producing IFN-g in response to M2 82–90 (Fig. 4B).
RSV replicates to lower levels in C57Bl/6 mice
compared to BALB/c mice following RSV challenge, and
C57Bl/6 mice exhibit less severe illness following RSV
challenge. For this reason, we considered that the overall
magnitude of the T cell response may be lower in C57Bl/6
mice. We therefore determined the number of CD8+/CD3+
T cells present in the target organs during infection. The
absolute number of CD8+ T cells in both the lungs and
spleen was very similar in C57Bl/6 and BALB/c mice at
each time point (Figs. 5A and B). This result demonstrated
that, although the magnitude and composition of the
lymphocytic infiltrate is similar in the lungs of RSV-infected
C57Bl/6 and BALB/c mice, the RSV M187–195-specific
CTL response is slightly reduced in magnitude in C57Bl/6
mice relative to the M2 82–90-specific CTL response in
BALB/c mice.Discussion
With this report, we identify the first RSV-specific T cell
epitope in a strain of mice other than BALB/c. This epitope
is H-2Db-restricted and corresponds to aa 187–195 of the
RSV matrix protein, and is likely anchored by residues 191
(asparagine) and 195 (isoleucine). In this study, we found
several peptides that were positive by ELISpot analysis.
However, we only identified one instance in which adjacent
peptides were positive, the M181–195 and M185–199
peptides in C57Bl/6 mice. Because the ELISpot assay is
highly sensitive and our initial screen was performed with
adjacent, overlapping peptides, we reasoned that a legiti-
mate epitope would generate ELISpot positive results in
adjacent peptides. Two instances of positive ELISpot results
in adjacent peptides were seen with BALB/c responses to F
peptides (Table 2), but both of these findings have been
reported previously (Chang et al., 2001; Jiang et al., 2002).
We therefore chose to pursue the M181–195 and M185–
199 peptides, and confirmed by ICS that a true H-2Db-
restricted epitope was contained within the overlap region of
these two adjacent full-length peptides.
In the current study, we show that the kinetics of the
CTL response to the new M187–195 epitope parallels
what is observed with the immunodominant M2 82–90
Fig. 5. CD8+ T cell counts in RSV-infected C57Bl/6 and BALB/c mice.
C57Bl/6 and BALB/c mice were infected with RSV and sacrificed at days
4, 6, 8, 10, 15, and 30 post-infection. (A) The absolute number of lung
CD8+/CD3+ T cells was measured by flow cytometry through day 15 post-
infection. (B) The absolute number of memory CD8+/CD3+ T cells in the
spleen on day 30 post-infection was also measured by flow cytometry.
N = 5 on each day. The data shown are representative of 2 independent
experiments.
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peptide-specific T cell response in C57Bl/6 mice is lower
in magnitude than the M2 82–90 response in BALB/c,
consistent with previous observations that have shown
C57Bl/6 mice to be less permissive for RSV infection than
BALB/c mice. In one previous study, mice of different
strains were primed with a recombinant vaccinia virus that
expressed the G protein of RSV (Hussell et al., 1998). The
data indicate that virus titers in immunized C57Bl/6 mice
were 2–3 logs lower than immunized BALB/c mice,
which would be expected in a less permissive mouse
strain. We typically observe that peak virus titers in lung
are 1.5–2.0 log10 pfu/gram less in C57Bl/6 mice than in
BALB/c, but clearance occurs with similar kinetics (J.A.R
and B.S.G., unpublished observations). It is important to
note that our experiments reflect primary RSV infection in
mice, whereas the aforementioned study represents a res-ponse to a challenge after immunization with a single RSV
protein expressed by a recombinant vaccinia virus. These
observations led us to the conclusion that the response to
RSV is attenuated in C57Bl/6 mice. It is therefore not
surprising that the CD8 T cell response to the M187–195
epitope appears slightly attenuated when compared to the
previously described M2 82–90 epitope during primary
infection (Fig. 4A). Furthermore, the memory response is
similarly attenuated (Fig. 4B). These data are consistent
with previous observations showing that the memory
population arises from the expansion and contraction of
CD8+ T cells that initially respond to a primary infection
(Ahmed and Gray, 1996; Murali-Krishna et al., 1998).
Since the number of CD8+ T cells responding to M187–
195 was significantly reduced compared to M2 82–90, it
would be expected that fewer memory CD8+ T cells would
respond upon a secondary exposure to the epitope. This
work provides a valuable new tool to study CD8+ T cell
responses to RSV in C57Bl/6 mice.
This manuscript serves as the first description of an RSV
CD8+ T cell epitope in a strain of mice other than BALB/c.
It is likely that there are additional MHC class I-restricted
epitopes in both H-2d and H-2b mice that are yet to be
discovered, each one adding new tools for understanding
RSV disease pathogenesis and T cell biology. The T cell
response to viral infections is often the critical component of
effective immunity. In many instances, one dominant CD8+
T cell epitope exists, with multiple additional epitopes that
evoke a response that is far less robust to the dominant
epitope. In the case of RSV infection in BALB/c mice, the
M2 82–90 epitope appears dominant when compared to the
additional epitopes that have been described in the F protein
(Chang et al., 2001; Jiang et al., 2002; Johnstone et al.,
2004). While we have no other epitopes in C57Bl/6 mice for
a comparison, it would not be surprising to find that the
M187–195 epitope is dominant, especially since it was
discovered first. Future experiments are sure to reveal
additional H-2b-restricted epitopes in other RSV proteins.
However, the data from our ELISpot experiments showed
that the greatest response in C57Bl/6 mice was seen against
the M protein, so it is likely that M187–195 is the dominant
H-2b-restricted epitope.
It is interesting to note that in our ELISpot assays, the
greatest response was seen against the RSV F protein in
BALB/c mice, whereas in C57Bl/6 mice, the greatest
response was seen against the M protein. This suggests
several possibilities in terms of the overall viral CD8+ T cell
response. In some cases, it seems that the collective
response against several epitopes from one protein may be
greater than that of a single immunodominant epitope,
despite the fact that these epitopes are individually weaker
than the immunodominant epitope in question. Why one
protein would be more easily processed than another is
unknown, although in this case, the fact that RSV F is a
surface protein may be a factor. However, the F protein did
not induce a greater response than M in C57Bl/6 mice, so
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viral protein, the MHC restriction, or other factors. Another,
simpler explanation is that in BALB/c mice, an epitope that
is more dominant than M2 82–90 is contained within the F
protein and remains undiscovered, even though we saw the
greatest response against F in the previously identified
F85–93 epitope (Chang et al., 2001).
The murine model of RSV infection is an excellent
model to study the regulation and composition of immune
responses to RSV, despite its limitations as a model for
disease progression (Graham et al., 2002). Previously
identified CTL epitopes have been H-2d-restricted and
described in BALB/c mice. However, because many
transgenic and knockout mice are available only on genetic
backgrounds other than BALB/c, the identification of other
murine CTL epitopes is useful to expand the investigation of
the complex immune response elicited by RSV infection.
With our current description of an H-2Db-restricted CD8+ T
cell epitope, it will now be possible to explore more details
of CD8+ T cell-mediated immune responses to RSV in
C57Bl/6 mice, which serve as the background strain for a
plethora of genetically modified mice with selected immu-
nological defects currently unavailable on a BALB/c
background. Future studies with this new M187–195
epitope will provide the opportunity to answer important
questions about mechanisms of T cell regulation and
phenotypic properties associated with viral clearance or
immunopathology.Materials and methods
Mice
Pathogen-free BALB/c and C57Bl/6 female mice be-
tween the ages of 8 and 10 weeks were purchased from
Charles River Laboratories (Raleigh, NC). The mice were
cared for in accordance with the Guide for the Care and Use
of Laboratory Animals, as described previously (Graham et
al., 1988). Experiments were performed with age-matched
groups.
Cell lines and antibodies
HEp-2 cell monolayer cultures were used to determine
the titer of RSV from lung tissues. The P815 cell line was
purchased from the American Type Culture Collection
(ATCC) (Rockville, MD). L-Kb and L-Db cells were a gift
from Jonathan Yewdell and Jack Bennick (NIH, Bethesda,
MD). All cell lines were maintained in Eagle’s minimal
essential media containing 10% fetal bovine serum (10%
EMEM) and were supplemented with 2 mM glutamine,
10 U of penicillin G per ml, and 10 Ag of streptomycin
sulfate per ml. Cell lines were determined to be free of
mycoplasma contamination by analysis with the polymerase
chain reaction (ATCC).Virus infection
The RSV challenge stock was derived from the wild-
type RSV strain A2 by sonication of infected HEp-2
monolayer cultures as previously described (Graham et al.,
1988). Mice were anesthetized intramuscularly with keta-
mine (40 Ag/g body weight) and xylazine (6 Ag/g body
weight) prior to intranasal inoculation with 107 PFU live
RSV in 100 Al of 10% EMEM. Some mice were also
challenged with RSV at least 1 month after primary
infection. Challenge infections were performed identically
to primary immunizations. In the initial screening of the
peptide pool, mice were sacrificed at days 6, 8, or 14 post-
challenge. Additional experiments were performed with
mice at day 14 post-challenge.
Synthetic peptides
The peptides used in the initial ELISpot screens
corresponded to the fusion (F), putative attachment glyco-
protein (G), and matrix (M) proteins of subgroup A wild-
type RSV strain A2. The F peptides were 14 aa in length
overlapping adjacent peptides by 11 amino acids (Mimo-
topes Pty. Ltd., Clayton Victoria, Australia), and the G and
M peptides were 15 amino acids in length overlapping by 11
amino acids (Synpep Corporation, Dublin, CA) (Table 1).
Additional peptides were synthesized by New England
Peptide, Inc. (Fitchburg, MA) and confirmed to be greater
than 95% pure by analytical high-performance liquid
chromatography (HPLC) at the NIAID peptide core facility
(Bethesda, MD). To identify the optimal peptide epitope
within the reactive 15 aa peptides, we used three separate
computer algorithms as guides, SYFPEITHI (http://
www.syfpeithi.de/) (Rammensee et al., 1999), BIMAS
(http://bimas.dcrt.nih.gov/molbio/hla_bind/) (Parker et al.,
1994), and RANKPEP (http://www.mifoundation.org/Tools/
rankpep.html) (Reche et al., 2002).
RSV M2 82–90 (SYIGSINNI) is derived from the M2
protein of the RSV A2 strain, and influenza virus
nucleoprotein (NP) 147–155 (TYQRTRALV) is derived
from the influenza virus A/Puerto Rico/8/34 nucleoprotein.
Peptides were synthesized by Anaspec, Inc. (San Jose, CA),
and confirmed to be >95% pure by the NIAID peptide core
facility (Bethesda, MD). Both peptides are H-2Kd restricted.
ELISpots
IFN-g ELISpot assays were performed on freshly
isolated splenocytes essentially as previously described
(Rock and Crowe, 2003). Briefly, prior to the addition of
cells, 96-well polyvinylidene difluoride-backed plates
(MAIP S4510, Millipore, Bedford, MA) were coated with
10 ng/ml of anti-IFN-g monoclonal antibody (mAb) (clone
AN18, Mabtech, Stockholm, Sweden) in phosphate-
buffered saline (PBS) at 4 -C overnight. After washing
the plates three times with PBS, each plate was blocked by
J.A. Rutigliano et al. / Virology 337 (2005) 335–343342the addition of 200 Al R10 medium per well for at least 2 h at
room temperature. Peptides were added directly to wells in a
volume of 50 Al and then freshly isolated splenocytes were
added at a concentration of 105 cells/well in 50 Al of R10
media. The final concentration of the peptides in the
screening assay was 10 Am. The plates were incubated for
18–20 h at 37 -C in 5% CO2. The plates were then washed,
labeled with 2 Ag/ml biotinylated anti-IFN-g mAb (clone
R4-6A2, Mabtech) in PBS containing 0.5% fetal bovine
serum, and incubated at room temperature for 3 h. After
additional washes, avidin–peroxidase complex (Vector
Laboratories, Burlingame, CA) was added to each well in
PBS containing 0.1% Tween-20 for 1 h at room tempera-
ture. The plates were washed, and IFN-g producing cells
were detected after a 4 min color reaction using 100 Al of
AEC substrate [20 mg of 3-amino-9-ethylcarbazol (Sigma-
Aldrich) dissolved in 2.5 ml of dimethylformamide diluted
1:20 in 47.5 ml of sodium-acetate buffer + 25 Al 30%
H2O2]. IFN-g-producing cells were counted using a Zeiss
Axioplan II ELISpot reader system using KS 4.3 software
(Carl Zeiss, Thornwood, NY). Results were expressed as the
number of spot-forming cells (SFC) per 106 input cells. The
number of peptide-specific IFN-g-secreting T cells was
calculated by subtracting the negative control value from the
established SFC count.
Intracellular cytokine staining (ICS)
Peptides that induced significant numbers of IFN-g spot-
forming cells in immune animals by ELISpot were tested
subsequently by ICS for IFN-g production for further
confirmation. For ICS analysis, RSV-challenged mice were
sacrificed at day 14 post-infection, and their spleens
removed and disrupted by mashing between the frosted
ends of glass slides. Mononuclear cells were isolated on a
density gradient, and ICS was performed as previously
described (Rutigliano and Graham, 2004). Cells were
stained with fluorochrome-labeled antibodies against mouse
IFN-g, TNF-a, CD8, and CD3. Flow cytometry was
performed with a FACSCalibur cytometer (Becton Dick-
inson, San Jose, CA) argon ion laser at 15 mW and 488 nm.
Data were analyzed using FlowJo version 6.0 (Tree Star,
San Carlos, CA).
Cytotoxicity assays
Cytotoxicity assays were performed using a variation of
previously described fluorescent-based lytic assays (Betts et
al., 2003; Liu et al., 2002; Oehen and Brduscha-Riem, 1998;
van Stipdonk et al., 2003). Briefly, P815 (H-2d), L-Db, and
L-Kb target cells were pulsed with peptides (2 Ag/106 cells)
and incubated overnight at 37 -C. Separate P815 target cell
preps were pulsed with either RSV M2 82–90 or an
irrelevant influenza peptide (NP 147–155). Separate L-Db
and L-Kb target cell preps were pulsed with either RSV
M187–195 or the irrelevant influenza peptide. The nextmorning, RSV-infected mice were sacrificed at day 8 post-
infection and lung tissue was disrupted by mashing between
the frosted ends of glass slides. Lymphocytes were then
isolated on a density gradient. After the incubation, the
target cells were washed with PBS and labeled with 5-(and-
6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE).
RSV-pulsed targets were loaded with 5 AM CFSE (CFSE
high) and influenza-pulsed targets were loaded with 0.5 AM
CFSE (CFSE low), then washed in FBS and media three
times. The peptide-loaded, CFSE-stained targets were then
individually incubated with lymphocytes described above
for 2–4 h at 37 -C at various effector to target (E/T) ratios.
Equivalent numbers of CFSE high and CFSE low targets
were incubated simultaneously with the effectors. Because
the CFSE low targets express a peptide that should not be
recognized by the effectors, they should not be killed and
should not interfere with the response to the CFSE high
targets that express the RSV peptides. The cells were then
analyzed by flow cytometry, and the percent of RSV-
specific target cell lysis was calculated as 100(percent
CFSE high cells/percent CFSE low cells).Acknowledgments
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